Thank you for choosing ACROBiosystems. Would you rate our product and service？
Participate in the survey and you will have the chance to win the gift of your choice!
Thank you for choosing ACROBiosystems. Would you rate our product and service？
Participate in the survey and you will have the chance to win the gift of your choice!
| Project item | Indications | Research phase | Cooperation demands |
| BBS21008 | Solid tumors such as lung cancer, gastric carcinoma, esophagus cancer, cervical cancer. | Pre-clinical, CMC developing; | Project transfer or co-development. (the project’s company is in the startup stage and seek external cooperation to accelate drug research and development.) |
Flow Cytometry assay shows that PE-Labeled Human PD-1, Fc,His Tag (Cat. No. PD1-HP2F2) can bind to 293T cells overexpressing human PD-L1. 1 μL stock solution per million cells (QC tested).
Captured Mouse PD-1, Fc Tag (Cat. No. PD1-M5259) on Protein A Chip can bind Mouse PD-L1, His Tag (Cat. No. PD1-M5220) with an affinity constant of 2.16 μM as determined in SPR assay (Biacore T200) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Prolgolimab | BCD-100 | Approved | Biocad | Forteca | Russian Federation | Melanoma | Biocad | 2020-04-01 | Carcinoma, Non-Small-Cell Lung; Melanoma; Uterine Cervical Neoplasms | Details |
| Cemiplimab | REGN-2810; SAR-439684 | Approved | Regeneron Pharmaceuticals Inc | Libtayo | EU | Carcinoma, Basal Cell; Carcinoma, Non-Small-Cell Lung | Regeneron Ireland Uc | 2018-09-28 | Diffuse Intrinsic Pontine Glioma; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Melanoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Fallopian Tube Neoplasms; Glioma; Lymphoma; Carcinoma, Squamous Cell; Peritoneal Neoplasms; Ovarian Neoplasms; Hepatitis B; Prostatic Neoplasms; Central Nervous System Neoplasms; Skin Neoplasms; Hodgkin Disease; Glioblastoma; Carcinoma, Renal Cell; Carcinoma, Basal Cell; Squamous Cell Carcinoma of Head and Neck; Solid tumours | Details |
| Camrelizumab | SHR-1210; INCSHR-1210; HR-301210 | Approved | Suzhou Suncadia Biopharmaceuticals Co Ltd, Jiangsu Hengrui Medicine Co Ltd | 艾立妥, 艾瑞卡 | Mainland China | Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung | Suzhou Suncadia Biopharmaceuticals Co Ltd | 2019-05-29 | Respiratory Tract Neoplasms; Melanoma; Uterine Cervical Neoplasms; Gastrointestinal Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Lung Neoplasms; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma; Genital Neoplasms, Female; Urologic Neoplasms; Lymphoma, Extranodal NK-T-Cell; Solid tumours; Nasopharyngeal Carcinoma; Breast Neoplasms; Lung Diseases; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Hodgkin Disease; Carcinoma, Renal Cell; Stomach Neoplasms; Bronchial Neoplasms; Esophageal Neoplasms; Ovarian Neoplasms; Carcinoma, Bronchogenic | Details |
| Toripalimab | TAB-001; JS-001; SO-001 | Approved | Suzhou Union Biopharm Biosciences Co Ltd, Shanghai Junshi Biosciences Co Ltd | 拓益 | Mainland China | Carcinoma, Transitional Cell | Shanghai Junshi Biological Engineering Co Ltd | 2018-12-17 | Urinary Bladder Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Lymphoma; Esophageal Squamous Cell Carcinoma; Nasopharyngeal Carcinoma; Liposarcoma; Neuroendocrine Tumors; Solid tumours; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Esophageal Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Kidney Neoplasms | Details |
| Sintilimab | IBI-308 | Approved | Innovent Biologics(Suzhou) Co Ltd | Tyvyt, 达伯舒 | Mainland China | Carcinoma, Hepatocellular | Innovent Biologics(Suzhou) Co Ltd | 2018-12-24 | Lymphoma, Extranodal NK-T-Cell; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Melanoma; Carcinoma, Non-Small-Cell Lung; Esophageal Squamous Cell Carcinoma; Lung Neoplasms; Endometrial Neoplasms; Colorectal Neoplasms; Ovarian Neoplasms; Nasopharyngeal Carcinoma; Osteosarcoma; Adenocarcinoma of Lung; Hodgkin Disease; Pancreatic Neoplasms; Esophageal Neoplasms; Solid tumours | Details |
| Dostarlimab | WBP-285; TSR-042; ANB-011 | Approved | Anaptysbio | JEMPERLI | United States | Solid tumours | null | 2021-04-21 | Solid tumours; Ovarian Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
| Pembrolizumab | SCH-900475; h409A11; MK-3475 | Approved | Merck & Co Inc | 可瑞达, Keytruda | EU | Esophageal Neoplasms | Merck Sharp & Dohme Bv | 2014-09-04 | Head and Neck Neoplasms; Solid tumours; Biliary Tract Neoplasms; Ovarian Neoplasms; Kidney Neoplasms; Endocrine Gland Neoplasms; Lymphoma, B-Cell; Liver Neoplasms; Skin Melanoma; Leiomyosarcoma; Hematologic Neoplasms; Carcinoma; Anus Neoplasms; Esophageal Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Thoracic Neoplasms; Bronchial Neoplasms; Carcinoma, Merkel Cell; Viremia; Carcinoid Tumor; Rectal Neoplasms; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Ovarian Epithelial; Carcinoma, Transitional Cell; Neuroectodermal Tumors; Glioblastoma; Inflammatory Breast Neoplasms; Pancreatic Neoplasms; Colonic Neoplasms; Thyroid Carcinoma, Anaplastic; Neoplasms, Glandular and Epithelial; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Neoplasms, Squamous Cell; Skin Neoplasms; Nasopharyngeal Neoplasms; Adenocarcinoma of Lung; Salivary Gland Neoplasms; Urinary Bladder Neoplasms; Mesothelioma; Microsatellite instability-high cancer; Urologic Diseas | Details |
| Penpulimab | AK-105 | Approved | Zhongshan Akeso Biopharma Co Ltd | 安尼可 | Mainland China | Hodgkin Disease | Zhengda Tianqing Kangfang (Shanghai) Biomedical Technology Co Ltd | 2021-08-03 | Solid tumours; Hodgkin Disease; Neoplasms; Nasopharyngeal Carcinoma; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Nivolumab | ONO-4538; ono-0123; BMS-936558; MDX-1106; BMS-936558-01 | Approved | Bristol-Myers Squibb Company, Ono Pharmaceutical Co Ltd | 欧狄沃, Opdivo | EU | Esophageal Neoplasms | Bristol-Myers Squibb Pharma Eeig | 2014-07-04 | Diarrhea; Lung Neoplasms; Peritoneal Neoplasms; Ureteral Neoplasms; Genital Neoplasms, Female; Hepatitis C; Colorectal Neoplasms; Sarcoma, Ewing; Brain Neoplasms; Hepatitis B; Esophageal Squamous Cell Carcinoma; Lymphoma, Mantle-Cell; Neuroblastoma; Sarcoma; Cholangiocarcinoma; Breast Neoplasms; Microsatellite Instability; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Esophageal adenocarcinoma; Large intestine neoplasm; Thyroid Cancer, Papillary; Uterine Cervical Neoplasms; Adenocarcinoma; Neoplasm Metastasis; Carcinoma, Hepatocellular; Melanoma; Carcinoma, Non-Small-Cell Lung; Multiple Myeloma; Urogenital Neoplasms; Leukemia, Myeloid, Acute; Fallopian Tube Neoplasms; Lymphoma, Non-Hodgkin; Endometrial Neoplasms; Glioma; Lymphoma; Carcinoma, Squamous Cell; Chondrosarcoma; Irritable Bowel Syndrome; Carcinoma; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Stomach Neoplasms; Skin Melanoma; Liver Neoplasms; Leukemia; Carcinoma, Merkel Cell; Ependymoma; Solid tumours; Medullobl | Details |
| Tislelizumab | BGB-A317 | Approved | Beigene Ltd | 百泽安 | Mainland China | Carcinoma, Hepatocellular | Beigene (Shanghai) Biotechnology Co Ltd | 2019-12-26 | Lymphoma, Mantle-Cell; Melanoma; Leukemia, Lymphocytic, Chronic, B-Cell; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Carcinoma, Squamous Cell; Lymphoma, T-Cell; Lymphoma; Lung Neoplasms; Esophageal Squamous Cell Carcinoma; Lymphoma, T-Cell, Cutaneous; Lymphoma, Large-Cell, Anaplastic; Nasopharyngeal Carcinoma; Lymphoma, Extranodal NK-T-Cell; Lymphoma, T-Cell, Peripheral; Lymphoma, Follicular; Breast Neoplasms; Urinary Bladder Neoplasms; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Lymphoma, Large B-Cell, Diffuse; Hodgkin Disease; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Head and Neck Neoplasms; Lymphoma, B-Cell, Marginal Zone; Solid tumours | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| SL-279252 | TAK-252; SL-279252 | Phase 1 Clinical | Shattuck Labs | Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Lymphoma, Large B-Cell, Diffuse; Carcinoma, Transitional Cell; Hodgkin Disease; Melanoma; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung | Details |
| INSIX RA (Indus Biotech) | Clinical | Indus Biotech Pvt Ltd | Arthritis, Rheumatoid; Inflammation | Details | |
| dPD-1 hCD19 CART cell therapy (Innovative Cellular Therapeutics) | ICTCAR-014 | Phase 2 Clinical | Innovative Cellular Therapeutics Co Ltd | Lymphoma, Non-Hodgkin | Details |
| PD-1 knockout engineered T cells (Chengdu MedGenCell) | Phase 2 Clinical | West China Hospital Of Sichuan University, Chengdu Medgencell | Lung Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung | Details | |
| CD19-PD1-CAR T cell therapy (Chinese PLA General Hospital) | Phase 2 Clinical | Pla General Hospital | Lymphoma, B-Cell | Details | |
| PD-1 knockout engineered T cells (Anhui Kedgene Biotechnology) | Phase 2 Clinical | Anhui Kedgene Biotechnology, Hangzhou Cancer Hospital | Esophageal Neoplasms | Details | |
| W0180 | Phase 1 Clinical | Pierre Fabre Medicament | Neoplasms | Details | |
| Programmed cell death 1 antibody (Sun Yat-sen University) | Phase 2 Clinical | Sun Yat-Sen University | Carcinoma, Hepatocellular | Details | |
| PD-1 knockout EBV-CTL (Nanjing Medical University) | Phase 2 Clinical | Nanjing Medical University | Stomach Neoplasms; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Nasopharyngeal Neoplasms; Lymphoma | Details | |
| EBV-Specific TCR-T Cell therapy (Xinqiao Hospital of Chongqing) | Phase 2 Clinical | Chongqing Xinqiao Hospital | Squamous Cell Carcinoma of Head and Neck | Details | |
| IBI315 | IBI315; IBI-315 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd, Hanmi Pharmaceutical Co Ltd | Neoplasms | Details |
| Anti-CTLA-4 and PD-1 CAR-T cell therapy (Shanghai Cell Therapy Research Institute) | Phase 2 Clinical | Shanghai Cell Therapy Research Institute | Neoplasms | Details | |
| ONO-4685 | ONO-4685 | Phase 1 Clinical | Merus | Autoimmune Diseases | Details |
| YBL-006 | YBL-006; YBL 006 | Phase 1 Clinical | Solid tumours; Neoplasms | Details | |
| BCMA-PD1 CAR T cell therapy (General Hospital of the People's Liberation Army) | Phase 2 Clinical | People'S Liberation Army General Hospital Military Service | Multiple Myeloma | Details | |
| BCD-217 | BCD-217 | Phase 2 Clinical | Biocad | Melanoma | Details |
| PD-1 knockout engineered T cells (Cell Biotech) | Phase 1 Clinical | Cell Biotech | Carcinoma, Renal Cell; Urinary Bladder Neoplasms; Prostatic Neoplasms | Details | |
| Recombinant humanized anti-PD-1 monoclonal antibody (Shanxi Wichida Bright Pharmaceutical) | Phase 1 Clinical | Shanxiweiqidaguangming Pharmaceutical Co Ltd | Solid tumours | Details | |
| MiHA-loaded PD-L silenced DC vaccination (Radboud University) | Phase 2 Clinical | Radboud University Nijmegen | Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Multiple Myeloma; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin | Details | |
| GNR-051 | GNR-051 | Phase 1 Clinical | Generium Pharmaceuticals | Carcinoma, Renal Cell; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
| CA-170 | CA-170; AUPM-170 | Phase 2 Clinical | Aurigene | Solid tumours; Neoplasms | Details |
| Pidilizumab | CT-011; MDV-9300 | Phase 2 Clinical | Curetech | Carcinoma, Renal Cell; Lymphoma, Large B-Cell, Diffuse; Pancreatic Neoplasms; Multiple Myeloma; Lymphoma, Follicular; Prostatic Neoplasms; Hepatitis C; Colorectal Neoplasms; Leukemia, Myeloid, Acute; Glioma; Lymphoma; Lymphoma, Non-Hodgkin; Melanoma; Carcinoma, Hepatocellular; Hepatitis C, Chronic | Details |
| 9MW1111 | 9MW1111 | Phase 1 Clinical | Mabwell (Shanghai) Bioscience Co Ltd | Solid tumours | Details |
| IMU-201 | IMU-201 | Phase 1 Clinical | Imugene | Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung | Details |
| MEDI-0680 | AMP-514; MEDI-0680 | Phase 2 Clinical | Medimmune | Kidney Neoplasms; Lymphoma, B-Cell; Carcinoma, Renal Cell | Details |
| MEDI-5752 | MEDI-5752 | Phase 1 Clinical | Medimmune Llc | Solid tumours; Carcinoma, Renal Cell; Neoplasms | Details |
| STW204单抗 | STW-204 | Phase 1 Clinical | Suzhou Stainwei Biotech Inc | Solid tumours | Details |
| CMAB-819 | CMAB8-19 | Phase 1 Clinical | Sinomab Bioscience Ltd | Squamous Cell Carcinoma of Head and Neck; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | Details |
| CS-1003 | CS-1003 | Phase 3 Clinical | Cstone Pharmaceuticals | Solid tumours; Neoplasms; Lymphoma; Carcinoma, Hepatocellular | Details |
| IBI318 | IBI-318; LY-3434172; LY3434172 | Phase 2 Clinical | Eli Lilly And Company, Innovent Biologics(Suzhou) Co Ltd | Small Cell Lung Carcinoma; Lymphoma, Extranodal NK-T-Cell; Carcinoma, Squamous Cell; Carcinoma, Hepatocellular | Details |
| RB-0004 | RB-0004 | Phase 1 Clinical | Reyoung Pharmaceutical Co Ltd | Solid tumours; Lymphoma | Details |
| Recombinant humanized anti-PD-1 monoclonal antibody (Sinocelltech) | SCT-I10A | Phase 3 Clinical | Shenzhou Cell Engineering Co Ltd | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Lymphoma; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma; Carcinoma, Hepatocellular | Details |
| ONCR-177 | ONCR-177 | Phase 1 Clinical | Oncorus | Liver Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Skin Neoplasms; Triple Negative Breast Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Melanoma | Details |
| Recombinant humanized anti-PD-1 monoclonal antibody (Anhui Anke Biotechnology) | Phase 2 Clinical | Anhui Anke Biotechnology (Group) Co Ltd | Esophageal Neoplasms; Neoplasms; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Lymphoma; Lung Neoplasms | Details | |
| iPD1 CD19 eCAR-T therapy (Marino Biotechnology) | Phase 1 Clinical | Beijing Mali Biotechnology Co Ltd, Chengdu Yinhe Biomedicine Co Ltd | Lymphoma, B-Cell | Details | |
| Multiple target antigen stimulating cell therapy (HengRui YuanZheng Biotechnology) | Phase 1 Clinical | Hengrui Yuanzheng (Shanghai) Biotechnology Co Ltd | Solid tumours; Stomach Neoplasms | Details | |
| Recombinant human PD-1 antibody herpes simplex virus | Phase 1 Clinical | Yangshengtang Co Ltd, Xiamen University | Head and Neck Neoplasms; Liver Neoplasms; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Melanoma; Uterine Cervical Neoplasms | Details | |
| CD19 PD-1/CD28 CAR-T Cell Therapy (Second Affiliated Hospital School Of Zhejiang University School Of Medicine) | Phase 1 Clinical | Lymphoma, B-Cell | Details | ||
| Recombinant humanized anti-PD-1 monoclonal antibody (Bio-Thera) | BAT-1306 | Phase 2 Clinical | Bio-Thera Solutions Ltd | Solid tumours; Liver Neoplasms; Stomach Neoplasms; Colorectal Neoplasms | Details |
| MGD-019 (MacroGenics) | MGD-019 | Phase 1 Clinical | Macrogenics | Solid tumours; Skin Melanoma; Prostatic Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Nivolumab Biosimilar | LY-01015 | Phase 1 Clinical | Luye Pharma Group Ltd | Neoplasms | Details |
| JTX-4014 (Jounce Therapeutics) | JTX-4014 | Phase 2 Clinical | Jounce Therapeutics | Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| XmAb-23104 (Xencor) | Phase 1 Clinical | Xencor | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Sarcoma; Nasopharyngeal Carcinoma; Breast Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details | |
| CC-90006 | C-90006; CC-90006 | Phase 1 Clinical | Anaptysbio | Autoimmune Diseases; Psoriasis | Details |
| Sym-021 | Sym-021 | Phase 1 Clinical | Symphogen | Solid tumours; Lymphoma; Neoplasm Metastasis | Details |
| 609-A (SBio) | 609-A | Phase 1 Clinical | Shenyang Sunshine Pharmaceutical Co Ltd | Solid tumours | Details |
| Sasanlimab | RN-888; PF-6801591; PF-06801591 | Phase 3 Clinical | Pfizer Pharmaceuticals Ltd (China) | Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Carcinoma, Squamous Cell; Endometrial Neoplasms; Bile Duct Neoplasms; Prostatic Neoplasms; Sarcoma; Urinary Bladder Neoplasms; Solid tumours; Carcinoma, Transitional Cell; Carcinoma, Renal Cell; Carcinoma; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Ovarian Neoplasms | Details |
| Nivolumab/Relatlimab | BMS-986213; BMS-936558/BMS-986016 | Phase 3 Clinical | Bristol-Myers Squibb Company | Esophageal Neoplasms; Stomach Neoplasms; Melanoma | Details |
| MAX-10181 | MAX-10181; MAX-1 | Phase 1 Clinical | Guangzhou Maxinovel Pharmaceiticals Co Ltd | Solid tumours | Details |
| Recombinant humanized anti-PD-1 monoclonal antibody (Shandong Xinshidai Pharmaceutical) | Phase 2 Clinical | Shandong New Time Pharmaceutical Co Ltd | Lymphoma, T-Cell, Peripheral; Solid tumours; Carcinoma, Transitional Cell; Neurolymphomatosis; Lymphoma; Uterine Cervical Neoplasms | Details | |
| Spartalizumab | PDR-001 | Phase 3 Clinical | Novartis Pharma Ag | Sarcoma, Alveolar Soft Part; Neuroendocrine Tumors; Prostatic Neoplasms; Breast Neoplasms; Sarcoma; Nasopharyngeal Carcinoma; Gastrointestinal Stromal Tumors; Colorectal Neoplasms; Bone Marrow Diseases; Primary Myelofibrosis; Lung Neoplasms; Carcinoma, Pancreatic Ductal; Chordoma; Endometrial Neoplasms; Lymphoma; Esophageal Squamous Cell Carcinoma; Carcinoma, Squamous Cell; Leukemia, Myeloid, Acute; Esophageal adenocarcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma; Persistent Fetal Circulation Syndrome; Adenocarcinoma; Stomach Neoplasms; Solid tumours; Liver Neoplasms; Head and Neck Neoplasms; Leukemia; Leukemia, Myeloid; Kidney Neoplasms; Preleukemia; Hematologic Diseases; Carcinoma, Renal Cell; Carcinoma; Squamous Cell Carcinoma of Head and Neck; Ovarian Neoplasms; Triple Negative Breast Neoplasms; Lymphoma, Large B-Cell, Diffuse; Leukemia, Myelomonocytic, Chronic; Neoplasms, Squamous Cell; Pancreatic Neoplasms; Thyroid Carcinoma, Anaplastic; Small Cell Lung Carcinoma; Myelodysp | Details |
| Anti-PD1/anti-TIM3 bispecific antibody (L&L vision biopharmaceuticals) | Details | ||||
| SSGJ-705 | SSGJ-705 | Phase 1 Clinical | Shanghai Cp Guojian Pharmaceutical Co Ltd | Solid tumours | Details |
| HX-009 | HX-009 | Phase 2 Clinical | Hangzhou Hansi Biomedicine Co Ltd, Wuhan Hanxiong Biotechnology Co Ltd | Solid tumours; Liver Neoplasms; Hematologic Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
| MW-11 | MW-11 | Phase 1 Clinical | Mabwell (Shanghai) Bioscience Co Ltd | Solid tumours; Carcinoma, Renal Cell; Stomach Neoplasms; Carcinoma, Transitional Cell; Nasopharyngeal Neoplasms; Hodgkin Disease; Colorectal Neoplasms; Endometrial Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
| SSI-361 | LVGN-3616; SSI-361 | Phase 2 Clinical | Lyvgen Biopharma(HK)Ltd | Neoplasms | Details |
| Ezabenlimab | BI-754091 | Phase 2 Clinical | C.H. Boehringer Sohn Ag & Co. Kg | Head and Neck Neoplasms; Solid tumours; Rectal Neoplasms; Colonic Neoplasms; Neoplasms; Pancreatic Neoplasms; Colorectal Neoplasms; Carcinoma, Squamous Cell; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms | Details |
| SI-B003 | SI-B003 | Phase 1 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Solid tumours; Carcinoma, Renal Cell; Stomach Neoplasms; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Colorectal Neoplasms; Neoplasm Metastasis; Melanoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
| T3011疱疹病毒（深圳市亦诺微医药） | Phase 2 Clinical | Shenzhen Yinuowei Pharmaceutical Technology Co Ltd | Head and Neck Neoplasms; Solid tumours; Esophageal Neoplasms; Breast Neoplasms; Neoplasm Metastasis; Melanoma; Carcinoma, Non-Small-Cell Lung | Details | |
| Tebotelimab | PD-1 X LAG-3; MGD-013 | Phase 3 Clinical | Macrogenics | Small Cell Lung Carcinoma; Carcinoma, Hepatocellular; Adenocarcinoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Melanoma; Endometrial Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Ovarian Neoplasms; Triple Negative Breast Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Esophageal Neoplasms; Head and Neck Neoplasms; Biliary Tract Neoplasms; Solid tumours; Hematologic Neoplasms | Details |
| LZM-009 | LZM-009 | Phase 2 Clinical | Livzon（Group） Pharmaceutical Factory | Solid tumours; Thymoma; Carcinoma, Non-Small-Cell Lung | Details |
| IBI319 | IBI-319 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Neoplasms | Details |
| Recombinant human anti-PD-1 monoclonal antibody(Yiyi Health Technology) | Phase 1 Clinical | Shanghai Yunyi Health Technology Development Co Ltd | Neoplasms | Details | |
| MK-4280A | MK-4280A | Phase 1 Clinical | Moshadong R & D (China) Co Ltd, Msd Ireland (Carlow) Merck Sharp & Dohme Corp | Solid tumours | Details |
| IBI-321 | IBI-321 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours | Details |
| HLX-10 | HLX-10 | Phase 3 Clinical | Shanghai Henlius Biotech Co Ltd | Small Cell Lung Carcinoma; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Esophageal Squamous Cell Carcinoma; Carcinoma, Squamous Cell; Colorectal Neoplasms; Microsatellite Instability; Triple Negative Breast Neoplasms; Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Hepatitis B, Chronic; Squamous Cell Carcinoma of Head and Neck; Carcinoma; Head and Neck Neoplasms; Liver Neoplasms | Details |
| Recombinant human anti-PD-1 monoclonal antibody(Sumgen) | SG-001 | Phase 2 Clinical | Hangzhou Sumgen Biotechnology Co Ltd | Solid tumours; Carcinoma, Ovarian Epithelial; Mesothelioma; Peritoneal Neoplasms; Lymphoma; Fallopian Tube Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| JS201 | JS201 | Phase 1 Clinical | Shanghai Junshi Biosciences Co Ltd | Neoplasms | Details |
| AZD-7789 | AZD-7789 | Phase 2 Clinical | AstraZeneca Ag | Carcinoma, Non-Small-Cell Lung | Details |
| Recombinant humanized anti-PD-1 monoclonal antibody (Shanghai CP Guojian) | Phase 1 Clinical | Shanghai Cp Guojian Pharmaceutical Co Ltd | Solid tumours | Details | |
| AK-112 | AK-112 | Phase 2 Clinical | Zhongshan Akeso Biopharma Co Ltd | Ovarian Neoplasms; Solid tumours; Neoplasms; Small Cell Lung Carcinoma; Genital Neoplasms, Female; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Neoplasm Metastasis | Details |
| EMB-02 | Phase 2 Clinical | Shanghai Epimab Biotherapeutics, Inc | Solid tumours | Details | |
| INCB-086550 | INCB-086550 | Phase 2 Clinical | Incyte Corp | Solid tumours; Carcinoma, Renal Cell; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
| Cetrelimab | JNJ-3283; JNJ-63723283 | Phase 3 Clinical | Johnson & Johnson | Carcinoma, Transitional Cell; Neoplasms; Multiple Myeloma; Urinary Bladder Neoplasms | Details |
| RO-7247669 | RO-7247669 | Phase 2 Clinical | F. Hoffmann-La Roche Ltd | Solid tumours; Esophageal Squamous Cell Carcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
| RO-7121661 | RG-7769; RO-7121661 | Phase 2 Clinical | F. Hoffmann-La Roche Ltd | Solid tumours; Small Cell Lung Carcinoma; Esophageal Squamous Cell Carcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
| QL-1706 | QL-1706; PSB-205 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Solid tumours; Liver Neoplasms; Neoplasms | Details |
| TY-101 | TY-101; TY101 | Phase 2 Clinical | Tayu Huaxia Biotech Medical Group Co Ltd | Solid tumours; Lymphoma | Details |
| XmAb20717 | XmAb-20717 | Phase 2 Clinical | Xencor | Breast Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Melanoma; Endometrial Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Neuroendocrine; Thymoma; Colorectal Neoplasms; Astrocytoma; Prostatic Neoplasms; Vulvar Neoplasms; Solid tumours; Nasopharyngeal Carcinoma; Cholangiocarcinoma; Adnexal Diseases; Mesothelioma; Carcinoma, Ovarian Epithelial; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Basal Cell; Carcinoma, Renal Cell | Details |
| Budigalimab | ABBV-181 | Phase 2 Clinical | Abbvie Inc | Ovarian Neoplasms; Solid tumours; Head and Neck Neoplasms; HIV Infections; Squamous Cell Carcinoma of Head and Neck; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| AK-104 | AK-104 | Phase 3 Clinical | Zhongshan Akeso Biopharma Co Ltd | Lymphoma, T-Cell, Peripheral; Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Microsatellite instability-high cancer; Nasopharyngeal Carcinoma; Uterine Cervical Neoplasms; Adenocarcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
| Retifanlimab | INCMGA-0012; INCMGA-00012; MGA-012 | Phase 3 Clinical | Macrogenics | Carcinoma, Transitional Cell; Carcinoma, Endometrioid; Melanoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Endometrial Neoplasms; Carcinoma, Squamous Cell; Prostatic Neoplasms; Urinary Bladder Neoplasms; Triple Negative Breast Neoplasms; Solid tumours; Esophageal Neoplasms; Carcinoma, Merkel Cell; Stomach Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Anus Neoplasms; Ovarian Neoplasms; Head and Neck Neoplasms | Details |
| AMG-404 | AMG-404 | Phase 1 Clinical | Amgen Inc | Solid tumours; Small Cell Lung Carcinoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prostatic Neoplasms | Details |
| AZD-2936 | AZD-2936 | Phase 2 Clinical | Astrazeneca Plc | Carcinoma, Non-Small-Cell Lung | Details |
This web search service is supported by Google Inc.
A-Z
